| Identification | Back Directory | [Name]
sodium 3-[1-[(4-chlorophenyl)methyl]-5-(quinolin-2-ylmethoxy)-3-tert-butylsulfanyl-indol-2-yl]-2,2-dimethyl-propanoate | [CAS]
147030-01-1 | [Synonyms]
MK 591
Quiflapon SodiuM
QUIFLAPON SODIUM; MK-591; MK 591
sodium 3-[1-[(4-chlorophenyl)methyl]-5-(quinolin-2-ylmethoxy)-3-tert-butylsulfanyl-indol-2-yl]-2,2-dimethyl-propanoate
1-[(4-Chlorophenyl)Methyl]-3-[(1,1-diMethylethyl)thio]-α,α-diMethyl-5-(2-quinolinylMethoxy)-1H-Indole-2-propanoic Acid SodiuM Salt | [Molecular Formula]
C34H34ClN2NaO3S | [MDL Number]
MFCD15143438 | [MOL File]
147030-01-1.mol |
| Chemical Properties | Back Directory | [storage temp. ]
-20°C | [solubility ]
DMSO : 50 mg/mL (82.08 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) | [form ]
Powder | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Quiflapon is a synthetic compound which specifically inhibits the activity of 5-Lox and is currently under development for the treatment of asthma. Also, Quiflapon, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells. | [Biological Activity]
Cell permeable: yes''Primary Target
FLAP | [in vivo]
Hyperoxia groups of mice treated with Quiflapon sodium (MK591) (20, 40 mg/kg) show alveolarization that resembles that of room air controls while untreated hyperoxia groups show definite evidence of aberrant alveolarization but no inflammation[3]. Comparison of the Aβ-immunopositive areas between the placebo and Quiflapon sodium (MK591) (320 mg/kg)-treated group reveals a statistically significant reduction of the amyloid burden in the treated mice. Quiflapon sodium also has a significant reduction in brain levels of IL-1β. Mice treated with Quiflapon sodium show a statistically significant decrease in the steady-state levels of total CREB and its phosphorylated form at Ser133[4]. | [target]
FLAP |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
|